Drug Profile
Dronabinol - Michael James Enterprises
Latest Information Update: 22 Feb 2022
Price :
$50
*
At a glance
- Originator RP Capital Group
- Developer Michael James Enterprises; University of Illinois at Chicago
- Class Antidementias; Antiemetics; Antineoplastics; Appetite stimulants; Cannabinoids; Chromans; Muscle relaxants; Non-opioid analgesics; Small molecules
- Mechanism of Action Cannabinoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Sleep apnoea syndrome